169 related articles for article (PubMed ID: 9010262)
1. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.
Jodo S; Kobayashi S; Kayagaki N; Ogura N; Feng Y; Amasaki Y; Fujisaku A; Azuma M; Yagita H; Okumura K; Koike T
Clin Exp Immunol; 1997 Jan; 107(1):89-95. PubMed ID: 9010262
[TBL] [Abstract][Full Text] [Related]
2. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.
Knipping E; Krammer PH; Onel KB; Lehman TJ; Mysler E; Elkon KB
Arthritis Rheum; 1995 Dec; 38(12):1735-7. PubMed ID: 8849344
[TBL] [Abstract][Full Text] [Related]
3. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
4. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.
Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Otsuki T; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1997 Nov; 110(2):303-9. PubMed ID: 9367417
[TBL] [Abstract][Full Text] [Related]
5. Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus.
Sahebari M; Rezaieyazdi Z; Nakhjavani MJ; Hatef M; Mahmoudi M; Akhlaghi S
Rheumatol Int; 2012 Mar; 32(3):601-6. PubMed ID: 21120501
[TBL] [Abstract][Full Text] [Related]
6. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.
Goel N; Ulrich DT; St Clair EW; Fleming JA; Lynch DH; Seldin MF
Arthritis Rheum; 1995 Dec; 38(12):1738-43. PubMed ID: 8849345
[TBL] [Abstract][Full Text] [Related]
7. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
[TBL] [Abstract][Full Text] [Related]
9. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.
Christensson M; Pettersson E; Eneslätt K; Christensson B; Bratt J; Rantapää-Dahlqvist S; Sundqvist KG
J Clin Immunol; 2002 Jul; 22(4):220-7. PubMed ID: 12148596
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus.
Tokano Y; Miyake S; Kayagaki N; Nozawa K; Morimoto S; Azuma M; Yagita H; Takasaki Y; Okumura K; Hashimoto H
J Clin Immunol; 1996 Sep; 16(5):261-5. PubMed ID: 8886994
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus.
Al-Maini MH; Mountz JD; Al-Mohri HA; El-Ageb EM; Al-Riyami BM; Svenson KL; Zhou T; Richens ER
Lupus; 2000; 9(2):132-9. PubMed ID: 10787011
[TBL] [Abstract][Full Text] [Related]
12. Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran.
Sahebari M; Hatef MR; Rezaieyazdi Z; Abbasi M; Abbasi B; Mahmoudi M
Arch Iran Med; 2010 Mar; 13(2):135-42. PubMed ID: 20187668
[TBL] [Abstract][Full Text] [Related]
13. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
[TBL] [Abstract][Full Text] [Related]
14. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
15. Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease.
Silvestris F; Williams RC; Calvani N; Grinello D; Tucci M; Cafforio P; Dammacco F
Clin Exp Med; 2002 May; 2(1):13-27. PubMed ID: 12049185
[TBL] [Abstract][Full Text] [Related]
16. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of soluble Fas ligand in patients with silicosis.
Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble Fas levels in patients with autoimmune rheumatic diseases.
Sahin M; Aydintug O; Tunc SE; Tutkak H; Naziroğlu M
Clin Biochem; 2007 Jan; 40(1-2):6-10. PubMed ID: 17056024
[TBL] [Abstract][Full Text] [Related]
19. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
Kawahito K; Misawa Y; Fuse K
Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.
Jodo S; Kobayashi S; Nakajima Y; Matsunaga T; Nakayama N; Ogura N; Kayagaki N; Okumura K; Koike T
Clin Exp Immunol; 1998 May; 112(2):166-71. PubMed ID: 9649177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
